AC Immune (ACIU) Competitors $2.00 +0.01 (+0.50%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.96 -0.04 (-1.95%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. REPL, COGT, DAWN, EOLS, AVDL, AVXL, PHVS, CDMO, QURE, and ABCLShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Replimune Group (REPL), Cogent Biosciences (COGT), Day One Biopharmaceuticals (DAWN), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Anavex Life Sciences (AVXL), Pharvaris (PHVS), Avid Bioservices (CDMO), uniQure (QURE), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Replimune Group Cogent Biosciences Day One Biopharmaceuticals Evolus Avadel Pharmaceuticals Anavex Life Sciences Pharvaris Avid Bioservices uniQure AbCellera Biologics Replimune Group (NASDAQ:REPL) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations. Is REPL or ACIU more profitable? AC Immune's return on equity of -28.26% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -54.84% -42.97% AC Immune N/A -28.26%-18.98% Which has more risk and volatility, REPL or ACIU? Replimune Group has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Does the media prefer REPL or ACIU? In the previous week, Replimune Group had 2 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for Replimune Group and 3 mentions for AC Immune. Replimune Group's average media sentiment score of 1.52 beat AC Immune's score of 0.78 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AC Immune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, REPL or ACIU? AC Immune has higher revenue and earnings than Replimune Group. AC Immune is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.07-3.40AC Immune$27.31M7.35-$60.41M-$0.58-3.45 Does the MarketBeat Community believe in REPL or ACIU? AC Immune received 90 more outperform votes than Replimune Group when rated by MarketBeat users. However, 64.02% of users gave Replimune Group an outperform vote while only 62.56% of users gave AC Immune an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16964.02% Underperform Votes9535.98% AC ImmuneOutperform Votes25962.56% Underperform Votes15537.44% Do analysts rate REPL or ACIU? Replimune Group presently has a consensus price target of $19.43, indicating a potential upside of 85.92%. AC Immune has a consensus price target of $12.00, indicating a potential upside of 500.00%. Given AC Immune's higher possible upside, analysts clearly believe AC Immune is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13AC Immune 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of REPL or ACIU? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryReplimune Group beats AC Immune on 10 of the 17 factors compared between the two stocks. Remove Ads Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$200.82M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.02%P/E Ratio-4.357.2023.1319.03Price / Sales7.35226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.946.476.944.33Net Income-$60.41M$141.90M$3.20B$247.06M7 Day Performance-7.41%-3.05%-2.30%-0.52%1 Month Performance-21.57%-4.63%3.10%-3.73%1 Year Performance-33.99%-8.61%11.22%1.74% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune2.4968 of 5 stars$2.00+0.5%$12.00+500.0%-34.0%$200.82M$27.31M-4.35140Short Interest ↑Gap UpREPLReplimune Group3.8551 of 5 stars$11.05+2.1%$19.43+75.8%+26.7%$851.02MN/A-3.60210Positive NewsCOGTCogent Biosciences2.4137 of 5 stars$7.40+3.4%$14.43+95.0%+1.4%$842.49MN/A-2.9880Positive NewsDAWNDay One Biopharmaceuticals2.9913 of 5 stars$8.31+1.0%$34.57+316.0%-48.1%$842.26M$131.16M-8.0760Analyst ForecastEOLSEvolus3.9948 of 5 stars$13.00-0.2%$24.67+89.7%-12.6%$826.63M$266.27M-14.29170AVDLAvadel Pharmaceuticals3.3628 of 5 stars$8.53-0.5%$19.88+133.0%-51.8%$824.25M$169.12M-10.8070Positive NewsAVXLAnavex Life Sciences3.7863 of 5 stars$9.61-1.3%$44.00+357.9%+88.5%$817.47MN/A-17.4740Positive NewsPHVSPharvaris1.4403 of 5 stars$15.47+0.5%$40.50+161.8%-33.7%$808.93MN/A-5.5330Gap UpCDMOAvid Bioservices1.0299 of 5 stars$12.50+0.1%$12.25-2.0%+79.0%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure2.6975 of 5 stars$14.77+7.8%$38.89+163.3%+142.7%$798.72M$27.12M-2.98500ABCLAbCellera Biologics2.4747 of 5 stars$2.59+6.1%$7.00+170.3%-47.4%$771.79M$28.83M-4.25500Positive News Remove Ads Related Companies and Tools Related Companies Replimune Group Competitors Cogent Biosciences Competitors Day One Biopharmaceuticals Competitors Evolus Competitors Avadel Pharmaceuticals Competitors Anavex Life Sciences Competitors Pharvaris Competitors Avid Bioservices Competitors uniQure Competitors AbCellera Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
